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Introduction: Patients with metastatic nasopharyngeal carcinoma (NPC) have variable survival outcomes. We
have previously shown that an elevated peripheral blood lymphocyte-to-monocyte ratio (LMR) is associated with
an increased metastatic risk in patients with primary NPC. The present study aimed to investigate the prognostic
value of pretreatment LMR in a large cohort of metastatic NPC patients.
Methods: Clinical data of 672 patients with metastatic NPC diagnosed between January 2003 and December
2009 were analyzed. The peripheral lymphocyte and monocyte counts were retrieved, and LMR was calculated.
Receiver operating characteristic (ROC) curve analysis and univariate and multivariate COX proportional hazards
analyses were performed to evaluate the association of LMR with overall survival (OS).
Results: Univariate analysis revealed that an elevated absolute lymphocyte count (≥1.390 × 109/L) and LMR
(≥2.475) as well as a decreased monocyte count (<0.665 × 109/L) were significantly associated with prolonged
OS. Multivariate Cox proportional hazard analysis showed that LMR (hazard ratio [HR] = 0.50, 95 % confidence
interval [CI] = 0.41–0.60, P < 0.001), absolute lymphocyte count (HR = 0.77, 95 % CI = 0.64–0.93, P = 0.007), and
monocyte count (HR = 1.98, 95 % CI = 1.63–2.41, P < 0.001) were independent prognostic factors. By stratification
analyses, only LMR remained a significant predictor of prognosis.
Conclusion: We identified pretreatment LMR as an independent prognostic factor for patients with metastatic NPC.
Independent validation of our findings is needed.
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Nasopharyngeal carcinoma (NPC) is a squamous cell
carcinoma that occurs in the epithelial lining of the
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creativecommons.org/publicdomain/zero/1.0/China and Southeast Asia [1, 2]. With the increasing
application of high-precision radiotherapy, distant fail-
ure is expected to become a predominant cause of
death from NPC [3, 4]. Once metastasis is diagnosed,
the overall survival (OS) of patients is typically under
15 months with palliative chemotherapy. Nevertheless,
retrospective studies have shown great differences in
the survival outcomes in patients with variable affected
anatomic sites and different numbers of metastases [5, 6].
For specific subgroups, OS may exceed 10 years [6]. There-
fore, a valuable marker to predict prognosis is desirable toicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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better outcomes for patients with metastatic NPC.
In the last decade, pretreatment peripheral differen-
tial leukocytes, such as lymphocytes and monocytes,
have been found to be associated with prognosis in
various cancers. A high pretreatment lymphocyte
count has been determined to be associated with the
good prognosis of patients with acute lymphoblastic
leukemia [7], metastatic gastric cancer [8], and NPC
[9]. A high monocyte count has been found to be a
poor independent prognostic factor in patients with
diffuse large B-cell lymphoma and metastatic melan-
oma [10]. An elevated lymphocyte-to-monocyte ratio
(LMR) has been reported to be a prognostic factor
for clinical outcome in patients with diffuse large B-
cell lymphoma and Hodgkin’s lymphoma [11]. Re-
cently, we have shown that an elevated LMR is associ-
ated with an increased metastatic risk in patients with
primary NPC [12]. However, there have been few stud-
ies of the prognostic value of LMR in patients with meta-
static NPC. Therefore, the current study was designed to
analyze the effect of pretreatment LMR on OS in these
patients.Patients and Methods
Patient selection and data collection
Clinical data of patients with metastatic NPC re-
ferred to Sun Yat-sen University Cancer Center
(SYSUCC) between January 2003 and December 2009
were reviewed. All of the included patients met the
following criteria: 1) pathologically confirmed World
Health Organization (WHO) type II or III NPC; 2)
radiographically detectable metastatic disease; 3) a
Karnofsky Performance Status score of ≥70; and 4)
available clinical information and laboratory data at
the diagnosis of metastasis. The exclusion criteria
were as follows: 1) patients with a self-reported acute
infection or hematologic disorder and 2) those with
another type of malignancy. The Union for Inter-
national Cancer Control/American Joint Committee
on Cancer (UICC/AJCC) TNM classification system
(6th edition, 2002) was used for staging. This study
protocol was approved by the Clinical Ethics Review
Board of SYSUCC.
As part of the physical examination, peripheral blood
was collected before treatment, and both peripheral lym-
phocytes and monocytes were counted using a Sysmex
XE-5000 automated hematology analyzer (Sysmex,
Kobe, Japan). The peripheral LMR was calculated as
the ratio of the absolute peripheral lymphocyte count
to monocyte count. The serum antibody titers of
Epstein-Barr virus (EBV) immunoglobulin A against
virus capsid antigen (VCA/IgA) and early antigen(EA/IgA) were detected by enzyme-linked immuno-
sorbent assay [13].
Treatment and follow-up
According to our institutional guidelines for the palliative
treatment of metastatic NPC, cisplatin-based systemic
chemotherapy was provided to all patients as a basic treat-
ment. Definitive radiotherapy targeting both the primary
tumor and its regional lymph nodes (locoregional radio-
therapy, lrRT) was administered to the patients with metas-
tasis at presentation for local symptomatic relief or as a
part of a multidisciplinary approach, as previously described
[14–16]. The evaluation of tumor response to therapy was
based on a computed tomography (CT) or magnetic reson-
ance imaging (MRI) scan. After the treatment was com-
pleted, the patients were evaluated at 3-month intervals for
the first 3 years and every 6 months thereafter or until
death. The last follow-up date was December 31, 2013 for
all available patients.
Statistical analysis
Statistical analyses were performed using SPSS soft-
ware (version 16.0, SPSS Inc., Chicago, IL, USA). OS
was defined as the period between the first diagnosis
of metastatic NPC and death or the last follow-up.
The receiver operating characteristic (ROC) curve
analysis was performed to select the most appropri-
ate cut-off points for absolute lymphocyte and mono-
cyte counts as well as LMR to stratify the patients at
high risk of malignancy-related death. Univariate and
multivariate analyses of clinicopathologic variables
were performed using Cox proportional hazards
regression models. Actuarial OS was plotted against
time using the Kaplan–Meier method, and differences
between the survival curves were assessed using
the log-rank test. The correlation of LMR with differ-
ent clinicopathologic characteristics was evaluated
by Spearman’s rank correlation coefficient (r). The
chi-square test was used to analyze differences in
proportions. A two-sided P < 0.05 was considered
significant.Results
Patients’ characteristics
In total, the data for 672 patients were retrievable. The
baseline patient characteristics are shown in Table 1.
The median age at the time of diagnosis was 46 years
(range, 13–79 years), and 546 (81.2 %) patients were
male. Two hundred and ninety-seven (44.2 %) patients
had distant metastases at presentation. The bones (58.3 %)
were the most common site of metastasis, followed by the
liver (34.1 %), lung (31.2 %), and extraregional lymph nodes
(26.0 %). Most of the patients (84.4 %) had metastases at
Table 1 Clinicopathologic characteristics of the 672 patients with metastatic nasopharyngeal carcinoma (NPC)
Characteristic Total (cases) Deaths [cases (%)] Unadjusted HR (95 % CI) P value
Total 672 458
Gender
Male 546 371 (67.9) Reference 0.700
Female 126 87 (69.0) 1.05 (0.83, 1.32)
Age (years)
<46 316 213 (67.4) Reference 0.124
≥46 356 245 (68.8) 1.16 (0.96, 1.39)
T stage*
T1-2 273 184 (67.4) Reference 0.975
T3-4 399 274 (68.7) 1.00 (0.83, 1.20)
N stage*
N0-1 273 172 (63.0) Reference <0.001
N2-3 399 286 (71.7) 1.42 (1.18, 1.72)
Metastasis at presentation
Absent 375 261 (69.6) Reference 0.825
Present 297 197 (66.3) 0.98 (0.81, 1.18)
Number of metastatic lesions
1 105 51 (48.6) Reference <0.001
≥2 567 407 (71.8) 2.06 (1.54, 2.77)
Bone metastasis
Absent 280 196 (70.0) Reference 0.862
Present 392 262 (66.8) 1.02 (0.85, 1.22)
Liver metastasis
Absent 443 283 (63.9) Reference <0.001
Present 229 175 (76.4) 1.62 (1.34, 1,95)
Lung metastasis
Absent 462 309 (66.9) Reference 0.847
Present 210 149 (71.0) 0.98 (0.81, 1.19)
Extraregional lymph node metastasis
Absent 497 328 (66.0) Reference 0.060
Present 175 130 (74.3) 1.22 (0.99, 1.49)
EBV VCA/IgA
<1:80 80 48 (60.0) Reference 0.413
1:80–1:320 395 270 (68.4) 1.15 (0.84, 1.56)
≥1:640 197 140 (71.1) 1.17 (0.85, 1.63)
EBV EA/IgA
<1:10 128 84 (65.6) Reference 0.385
1:10–1:20 216 149 (69.0) 0.97 (0.74, 1.27)
≥1:40 328 225 (68.6) 0.91 (0.71, 1.16)
Lymphocyte count (× 109/L)
<1.390 340 250 (73.5) Reference 0.002
≥1.390 332 208 (62.7) 0.75 (0.63, 0.90)
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Table 1 Clinicopathologic characteristics of the 672 patients with metastatic nasopharyngeal carcinoma (NPC) (Continued)
Characteristic Total (cases) Deaths [cases (%)] Unadjusted HR (95 % CI) P value
Monocyte count (× 109/L)
<0.665 428 263 (61.4) Reference <0.001
≥0.665 244 195 (80.0) 2.17 (1.80,2.62)
LMR
<2.475 335 269 (80.3) Reference <0.001
≥2.475 337 189 (56.1) 0.45 (0.37, 0.54)
HR, hazard ratio; CI, confidence interval; EBV, Epstein-Barr virus; VCA/IgA, immunoglobulin A against viral capsid antigen; EA/IgA, immunoglobulin A against early
antigen; LMR, lymphocyte-to-monocyte ratio. *The American Joint Committee on Cancer (AJCC) 2002 system was used for staging at the diagnosis of NPC
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458 (68.2 %) of the 672 patients died. The 1-, 2-, and 3-year
OS rates for the entire patient cohort were 81.1 %, 52.5 %,
and 37.2 %, respectively.
The mean lymphocyte and monocyte counts were
1.462 × 109/L (range, 0.100–5.850 × 109/L) and 0.607 × 109/
L (range, 0.020–2.300 × 109/L), respectively. The mean LMR
was 3.219 (range, 0.180–69.000). The cut-off points of the
absolute lymphocyte count, monocyte count, and LMR for
OS as determined by ROC curve analyses were 1.390 × 109/
L, 0.665 × 109/L, and 2.475, respectively (Fig. 1). A low LMR
(<2.475) was significantly correlated with metastasis after
radical therapy (r= 0.306, P < 0.001), involvement of more
than one metastatic site (r= −0.150, P < 0.001), liver metas-
tasis (r=−0.150, P < 0.001), and extraregional lymph node
metastasis (r=−0.100, P= 0.009) (Table 2).
Univariate Cox proportional hazards regression analysis
of clinicopathologic characteristics
As shown in Table 1, the absolute lymphocyte count,
monocyte count, LMR, and other clinicopathologic
characteristics (including age, gender, T stage, N stage,Fig. 1 Receiver operating characteristic (ROC) curve analyses of cut-off poin
lymphocyte-to-monocyte ratio (LMR) for overall survival (OS) analyses am
cut-off points of the lymphocyte count (a), monocyte count (b), and LMR
respectively. AUC, area under the ROC curvemetastasis at presentation, number of metastatic le-
sions, metastasis sites [i.e., the bones, liver, lungs, and
extraregional lymph nodes], and EBV-related antibodies
[i.e., serum VCA/IgA and IgA/EA antibodies]) were
subjected to univariate analysis. A higher absolute
lymphocyte count, lower absolute monocyte count, and
higher LMR were associated with longer OS (Fig. 2).
Other variables, including N stage (hazard ratio [HR] =
1.42, 95 % confidence interval [CI] = 1.18-1.72, P < 0.001),
number of metastatic lesions (HR = 2.06, 95 % CI = 1.54-
2.77, P < 0.001), and liver metastasis (HR = 1.62, 95 %
CI = 1.34-1.95, P < 0.001), were also found to be associated
with OS (Table 1).
Multivariate Cox proportional hazards regression analysis
of clinicopathologic characteristics
We used a multivariate model to adjust for the con-
founders of the association of LMR with survival. The
results showed that a high LMR was an independent
predictor of a favorable OS (HR = 0.50, 95 % CI =
0.41–0.60, P < 0.001) (Table 3 Model 1, including
LMR as a variable). In addition, both absolutets of baseline absolute lymphocyte and monocyte counts and
ong patients with metastatic nasopharyngeal carcinoma (NPC). The
(c) for OS analyses were 1.390 × 109/L, 0.665 × 109/L, and 2.475,
Table 2 Correlation of baseline LMR with clinicopathologic characteristics of patients with metastatic NPC
Characteristic LMR < 2.475 LMR≥ 2.475 r value P value
Total 335 337
Gender
Male 277 269 0.037 0.342
Female 58 68
Age (years)
<46 157 159 −0.003 0.935
≥46 178 178
T stage
T1-T2 136 137 <0.001 0.988
T3-T4 199 200
N stage
N0-N1 138 135 0.012 0.765
N2-N3 197 202
Metastasis at presentation
Absent 238 137 0.306 <0.001
Present 97 200
Number of metastatic lesions
1 34 71 −0.150 <0.001
≥2 301 266
Bone metastasis
Absent 139 141 −0.004 0.927
Present 196 196
Liver metastasis
Absent 197 246 −0.150 <0.001
Present 138 91
Lung metastasis
Absent 224 238 −0.041 0.294
Present 111 99
Extraregional lymph node metastasis
Absent 233 264 −0.100 0.009
Present 102 73
EBV VCA/IgA




<1:10 56 72 −0.055 0.151
1:10–1:20 109 107
≥1:40 170 158
Footnotes as in Table 1
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Fig. 2 Kaplan–Meier overall survival (OS) analysis for patients with metastatic NPC. a, the OS rate was higher in the patients with a high absolute
lymphocyte count than in those with a low count (P = 0.002). b, the OS rate was lower in the patients with a high absolute monocyte count
than in those with a low count (P < 0.001). c, the OS rate was higher in the patients with a high LMR than in those with a low LMR (P < 0.001). LY,
lymphocyte; MO, monocyte
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their independence from other covariates using the
Cox model (Table 3 Model 2, including lymphocyte
and monocyte counts as variables). LMR was not in-
cluded here, considering the multicollinearity between
LMR and absolute lymphocyte and monocyte counts.
The results showed that the absolute lymphocyte
count was an independent factor for a favorable
prognosis (HR = 0.77, 95 % CI = 0.64–0.93, P = 0.007),
whereas the absolute monocyte count was an inde-
pendent inferior prognostic factor for patients with
metastatic NPC (HR = 1.98, 95 % CI = 1.63–2.41, P
<0.001) (Table 3 Model 2). After stratification by T
stage, N stage, metastasis at presentation, metastasis
after radical therapy, number of metastatic lesions,
and metastatic sites, only LMR remained a significant
predictor of prognosis (Figs. 3, 4 and 5). Moreover,
an advanced N stage, the presence of two or more
lesions, and liver metastasis were shown to be inde-
pendent indicators of short OS (Table 3).Table 3 Multivariate analysis of prognostic factors in patients with m
Characteristic
HR (95 %
N stage (N2-3 vs. N0-1) 1.42(1.18,
Number of metastatic lesions (≥2 vs. 1) 1.73(1.29,
Liver metastasis (present vs. absent) 1.38(1.14,
Lymphocyte count (≥1.390 × 109/L vs. <1.390 × 109/L) NA
Monocyte count (≥0.665 × 109/L vs. <0.665 × 109/L) NA
LMR (≥2.475 vs. <2.475) 0.50(0.41,
NA, not applicable. Other footnotes as in Table 1Discussion
In the current study, we demonstrated that an elevated
LMR was significantly associated with prolonged OS and
was independent of the other variables assessed in pre-
dicting the prognosis of patients with metastatic NPC.
Moreover, after stratification by T stage, N stage, metas-
tasis at presentation, metastasis after radical therapy,
number of metastatic lesions, and metastatic sites, LMR
remained a significant predictor of prognosis.
There is substantial evidence in advanced cancer that
the host systemic immune response is an important in-
dependent predictor of outcome and that pre-treatment
measures of the systemic inflammatory immune re-
sponse can be used to independently predict cancer pa-
tients’ survival [17]. Among many systemic inflammatory
measures, the white blood cell (WBC) subset count (the
neutrophil count [18] or the neutrophil-to-lymphocyte
ratio [19]) is well known as an independent prognostic
factor for survival [17]. However, evidence that LMR
may have a prognostic role in cancer is limited. Recentetastatic NPC
Model 1 Model 2
CI) P value HR (95 % CI) P value
1.72) <0.001 1.39(1.15,1.68) 0.001
2.32) <0.001 1.87(1.40,2.52) <0.001
1.67) 0.001 1.29(1.06,1.57) 0.010
NA 0.77(0.64,0.93) 0.007
NA 1.98(1.63,2.41) <0.001
0.60) <0.001 NA NA
Fig. 3 Kaplan-Meier OS analysis according to baseline absolute lymphocyte count in patients with metastatic NPC. In the T1-2 subgroup
(a), the T3-4 subgroup (b), the N0-1 subgroup (c), the N2-3 subgroup (d), the subgroup with metastasis after radical therapy (f), the subgroup with
multiple metastasis lesions (h), the bone metastasis subgroup (i), and the lung metastasis subgroup (k), the OS rates are higher in the patients with a
high absolute lymphocyte count than in those with a low count (all P < 0.05). In the subgroup with metastasis at presentation (e), the subgroup with
one metastasis lesion (g), the liver metastasis subgroup (j), and the extraregional lymph node metastasis subgroup (l), there is no significant difference
between the two curves (all P > 0.05)
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ciated with survival outcomes in classical Hodgkin’s
lymphoma [20], diffuse large B-cell lymphoma [21],
metastatic non-small cell lung cancer [22], and NPC
[12]. In the present study, we evaluated LMR as a
prognostic indicator in 672 patients with metastatic
NPC. Some of our results were consistent with previ-
ous findings. We found that an elevated LMR not
only had a strong correlation with longer survival but
also was an independent prognostic factor for sur-
vival, as determined by multivariate analysis using the
Cox model. However, some of our results differed
from those reported by Jin et al. [23], which have
shown that the absolute lymphocyte count was not
correlated with OS. In the current study, after adjust-
ing for confounders, the absolute lymphocyte count
remained as an independent prognostic factor for OS.
The discordance between these two studies may be
partially due to the different sample sizes: 672 pa-
tients were recruited in this study compared with 229
in the study by Jin et al. [23].The mechanisms underlying the relationship between
LMR and the prognosis of cancer patients remain unclear,
which may be partially explained by the link between
chronic inflammation and cancers [24–26]. It is a consen-
sus that the adaptive immune system carries out immune
surveillance and can eliminate newly formed tumors; how-
ever, effective adaptive immune responses are always sup-
pressed in established tumors through several pathways,
including the inhibition of dendritic cell differentiation and
the activation and infiltration of regulatory T cells and
tumor-associated macrophages [24]. Lymphocytes are cru-
cial components of the adaptive immune system, and the
presence of tumor-infiltrating lymphocytes has been re-
ported to indicate the generation of an effective antitumor
cellular immune response [27]. The peritumoral inflamma-
tory response is thought to reflect the interaction between
the tumor and the host. In previous studies, a high lympho-
cytic infiltrate has been linked with prolonged survival, in-
dependent of clinicopathologic characteristics, in breast
cancer patients [28]. However, data supporting the associ-
ation between intratumoral immune cells and blood-based
Fig. 4 Kaplan-Meier OS analysis according to baseline absolute monocyte count in patients with metastatic NPC. In the T1-2 subgroup
(a), the T3-4 subgroup (b), the subgroup with metastasis at presentation (e), the subgroup with multiple metastasis lesions (h), the bone
metastasis subgroup (i), the liver metastasis subgroup (j), the lung metastasis subgroup (k), and the extraregional lymph node metastasis
subgroup (l), the OS rates are lower in the patients with a high absolute monocyte count than in those with a low count (all P < 0.05). In the
N0-1 subgroup (c), the N2-3 subgroup (d), and the subgroup with metastasis after radical therapy (f), the OS rate is higher in the patients with a high
absolute monocyte count than in those with a low count (all P < 0.001). In the subgroup with one metastasis lesion (g), there is no significant
difference between the two curves (P = 0.070)
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OS are sparse. Previous studies have demonstrated an asso-
ciation between a low peripheral blood lymphocyte count
and short survival in patients with different types of cancer
[29, 30]. We have previously shown prolonged survival of
primary NPC patients with elevated lymphocyte counts
compared with those with decreased lymphocyte counts
[12]. Monocytes are a subset of circulating white
blood cells that can further differentiate into a
range of tissue macrophages and dendritic cells
[31]. It has been reported that monocytes secrete
various proinflammatory cytokines, such as interleu-
kin (IL)-1, IL-6, IL-10, and tumor necrosis factor-α
(TNF-α), which have been associated with short
survival and poor prognosis in patients with malig-
nancy [32, 33]. Moreover, monocytes release mono-
cyte chemo-attractant protein-1 (MCP-1) upon
stimulation and mediate tumor-associated macro-
phage infiltration in solid tumors, which have beenshown to produce a variety of chemokines, such as
transforming growth factor-α (TGF-α), TNF-α, IL-1,
and IL-6, to promote tumorigenesis, angiogenesis,
and distant metastasis of malignant tumors [34, 35].
As a consequence, a high absolute monocyte count
may indicate poor prognosis. Our findings also
showed that a high monocyte count was signifi-
cantly associated with short survival in patients
with metastatic NPC.
LMR, which is defined as the absolute lymphocyte
count divided by the absolute monocyte count, may
reflect the diverse effects of monocytes and lympho-
cytes on tumor progression. Previous studies have
demonstrated that normal human monocytes suppress
either the phytohemagglutinin- or antigen-induced
lymphocyte proliferative response when the monocyte-
to-lymphocyte ratio is increased [36]. In the current
study, although the lymphocyte count or monocyte
count alone could predict the survival outcomes in
Fig. 5 Kaplan-Meier OS analysis according to baseline LMR in patients with metastatic NPC. In the T1-2 subgroup (a), the T3-4 subgroup
(b), the N0-1 subgroup (c), the N2-3 subgroup (d), the subgroup with metastasis at presentation (e), the subgroup with metastasis after
radical therapy (f), the subgroup with one metastasis lesion (g), the subgroup with multiple metastasis lesions (h), the bone metastasis subgroup
(i), the liver metastasis subgroup (j), the lung metastasis subgroup (k), and the extraregional lymph node metastasis subgroup (l), the OS rates are
higher in the patients with a high LMR than in those with a low LMR (all P < 0.01)
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them in this regard. Our results of multivariate Cox
proportional hazard analysis showed that LMR and
absolute lymphocyte and monocyte counts were
independent prognostic factors. However, after strati-
fication analysis, only LMR remained a significant
predictor of prognosis. In addition, consistent with
the findings of Pan et al. [37], we found that an ad-
vanced N stage, the presence of two or more meta-
static lesions, and liver metastasis were independent
prognostic factors for short OS, whereas lung or
bone metastases were not associated with OS. We
postulate that these findings may be associated with
a unique biological behavior of NPC in the liver me-
tastasis group.Conclusion
Our results show that LMR can function as an inde-
pendent prognostic factor for patients with metastatic
NPC. Moreover, this ratio can be easily determined
with routine blood counts and is readily applicableclinically. We acknowledge that our findings are limited
by the retrospective and single center nature of this
study; thus, further independent validation of our find-
ings is warranted.
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